Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 191: Which of the following is the most likely adverse effect of metoclopramide?

A. Tardive dyskinesia (Correct Answer)
B. Hyperactivity
C. Hyperthyroidism
D. Hallucinations

Explanation: **Explanation:** **Metoclopramide** is a potent prokinetic agent and antiemetic. Its primary mechanism of action involves blocking **D2 (Dopamine) receptors** in the Chemoreceptor Trigger Zone (CTZ) and the gastrointestinal tract [1], [3]. **Why Option A is Correct:** Metoclopramide crosses the blood-brain barrier and blocks D2 receptors in the **nigrostriatal pathway** (basal ganglia). This blockade can lead to **Extrapyramidal Side Effects (EPS)**, similar to antipsychotic medications [1]. While acute dystonia is common in younger patients [1], **Tardive Dyskinesia** (characterized by involuntary, repetitive movements of the face, tongue, or limbs) is a serious, often irreversible adverse effect associated with chronic or high-dose use [3]. **Why Other Options are Incorrect:** * **B. Hyperactivity:** Metoclopramide typically causes sedation, drowsiness, and lassitude due to its central nervous system effects, rather than hyperactivity. * **C. Hyperthyroidism:** There is no known association between metoclopramide and thyroid dysfunction. However, it does cause **Hyperprolactinemia** (leading to galactorrhea or gynecomastia) because dopamine normally inhibits prolactin release [2], [3]. * **D. Hallucinations:** While CNS side effects like anxiety or depression can occur, hallucinations are not a characteristic adverse effect of D2 antagonists like metoclopramide. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** Metoclopramide is a preferred agent for **Diabetic Gastroparesis**. * **Contraindication:** It is strictly contraindicated in **Pheochromocytoma** (can cause a hypertensive crisis) and **Mechanical Bowel Obstruction**. * **Alternative:** **Domperidone** is a D2 antagonist that does *not* cross the blood-brain barrier, making it less likely to cause EPS/Tardive dyskinesia.

Question 192: In peptic ulcer disease, what is the primary current use of antacids?

A. Prompt pain relief (Correct Answer)
B. Ulcer healing
C. Preventing ulcer relapse
D. Control of bleeding from the ulcer

Explanation: In modern gastroenterology, the role of antacids has shifted from primary therapy to **symptomatic management** [1]. **1. Why "Prompt pain relief" is correct:** Antacids are weak bases that react with gastric hydrochloric acid to form salt and water [2]. This chemical neutralization results in an immediate increase in gastric pH. By reducing acidity, antacids quickly decrease the irritation of the ulcer base and inhibit the activity of pepsin (which is inactive above pH 4), leading to **rapid, albeit short-lived, relief of dyspeptic pain** [1]. Because they act instantly upon contact with acid, they are the preferred "rescue" medication for breakthrough pain. **2. Why other options are incorrect:** * **Ulcer healing:** While high-dose antacids *can* heal ulcers, they require frequent dosing (7 times a day) to maintain efficacy. Proton Pump Inhibitors (PPIs) and H2 blockers are far more potent and are now the gold standard for healing. * **Preventing ulcer relapse:** Antacids have a short duration of action (1–3 hours) and do not address the underlying causes of recurrence, such as *H. pylori* infection or NSAID use [1]. * **Control of bleeding:** Bleeding ulcers require endoscopic intervention and IV PPIs to maintain a high gastric pH (>6) to stabilize clot formation. Antacids are ineffective in this acute setting. **High-Yield NEET-PG Pearls:** * **Milk-Alkali Syndrome:** Characterized by hypercalcemia, metabolic alkalosis, and renal failure; historically associated with excessive intake of Calcium Carbonate and milk. * **Drug Interactions:** Antacids can significantly decrease the absorption of drugs like **Tetracyclines, Quinolones, and Iron** by chelation or by altering gastric pH. * **Side Effects:** Magnesium salts cause **diarrhea** (osmotic), while Aluminum salts cause **constipation** [2]. Most commercial preparations combine both to balance bowel effects.

Question 193: Why should one avoid the combination of Ranitidine and Sucralfate in a patient with Peptic Ulcer Disease?

A. Sucralfate decreases the efficacy of Ranitidine.
B. Sucralfate becomes ineffective in the presence of Ranitidine. (Correct Answer)
C. The combination of these two drugs causes agranulocytosis.
D. This combination has no added benefit.

Explanation: **Explanation** The core concept behind this interaction is the **pH-dependent activation** of Sucralfate. **1. Why Option B is Correct:** Sucralfate is a complex of aluminum hydroxide and sulfated sucrose. It acts as a physical mucosal protectant by polymerizing into a sticky, viscous paste that binds to the ulcer base, creating a protective barrier against acid and pepsin. However, this polymerization process **requires an acidic environment (pH < 4)** to occur. Ranitidine is an $H_2$ receptor antagonist that suppresses gastric acid secretion and increases the intragastric pH. When given together, Ranitidine raises the pH, preventing Sucralfate from activating and forming the necessary protective paste. Thus, Sucralfate becomes therapeutically ineffective. **2. Why Other Options are Incorrect:** * **Option A:** The primary failure is not the efficacy of Ranitidine (which still successfully reduces acid), but the failure of Sucralfate to polymerize. * **Option C:** Neither Ranitidine nor Sucralfate is typically associated with agranulocytosis. (Note: Drugs like Clozapine or Antithyroid drugs are classic causes). * **Option D:** While the combination is indeed illogical, the specific pharmacological reason is the antagonism of Sucralfate’s mechanism of action, making "ineffectiveness" the most accurate clinical description. **3. High-Yield Clinical Pearls for NEET-PG:** * **Administration Timing:** To avoid this interaction, Sucralfate should be taken on an empty stomach **at least 30 minutes before** any antacids or $H_2$ blockers. * **Side Effects:** The most common side effect of Sucralfate is **constipation** (due to the aluminum content). * **Drug Interactions:** Sucralfate can adsorb other drugs (e.g., Phenytoin, Digoxin, Tetracycline, Ciprofloxacin), reducing their absorption. Maintain a 2-hour gap. * **Key Requirement:** Sucralfate is a "cytoprotective" agent, not an "antacid." It does not neutralize acid; it requires it.

Question 194: What is the best antiemetic for a patient undergoing radiotherapy?

A. Clonidine
B. Metoclopramide
C. Ondansetron (Correct Answer)
D. Cisapride

Explanation: **Explanation:** **Ondansetron** is the drug of choice for radiotherapy-induced nausea and vomiting (RINV) and chemotherapy-induced nausea and vomiting (CINV). **Mechanism of Action:** Radiotherapy causes cellular damage to the gastrointestinal mucosa, leading to the release of **serotonin (5-HT)** from enterochromaffin cells. This serotonin stimulates **5-HT3 receptors** on vagal afferents and in the Chemoreceptor Trigger Zone (CTZ). Ondansetron is a potent, selective 5-HT3 receptor antagonist that blocks these signals, effectively preventing the emetic reflex. **Analysis of Incorrect Options:** * **Clonidine (A):** An alpha-2 adrenergic agonist primarily used for hypertension and opioid withdrawal; it has no significant antiemetic properties. * **Metoclopramide (B):** A D2 receptor antagonist. While it has some prokinetic and antiemetic effects, it is significantly less effective than 5-HT3 antagonists for high-emetic stimuli like radiation and can cause extrapyramidal side effects. * **Cisapride (D):** A prokinetic agent that acts as a 5-HT4 agonist. It was largely withdrawn from the market due to the risk of fatal cardiac arrhythmias (QT prolongation/Torsades de Pointes) and is not used as an antiemetic. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** 5-HT3 antagonists (Ondansetron, Palonosetron) are DOC for CINV, RINV, and post-operative nausea/vomiting (PONV). * **Side Effects:** The most common side effects of Ondansetron are **headache** and **constipation**. It can also cause **QT interval prolongation**. * **Palonosetron:** A newer 5-HT3 antagonist with a longer half-life, often preferred for delayed emesis. * **Combination Therapy:** For highly emetogenic regimens, 5-HT3 antagonists are often combined with **Dexamethasone** and **Aprepitant** (NK1 receptor antagonist).

Question 195: All of the following are true about Metoclopramide except?

A. It is an antiemetic which blocks 5HT3 receptors
B. It has prokinetic action by 5HT4 agonism
C. It has D2 blocking action resulting in extrapyramidal side effects
D. It can be used for L-Dopa induced vomiting (Correct Answer)

Explanation: ### Explanation **Metoclopramide** is a substituted benzamide used primarily as a prokinetic and antiemetic. Understanding its multi-receptor mechanism is crucial for NEET-PG. **Why Option D is the Correct Answer (The False Statement):** Metoclopramide is a **central D2 receptor antagonist**. While this makes it an effective antiemetic, it allows the drug to cross the blood-brain barrier (BBB) and block dopamine receptors in the basal ganglia. In patients with Parkinson’s disease taking **L-Dopa**, metoclopramide would antagonize the therapeutic effects of L-Dopa and worsen parkinsonian symptoms (rigidity, tremors). * **Clinical Pearl:** For L-Dopa induced vomiting, **Domperidone** is the drug of choice because it is a peripheral D2 antagonist that does not cross the BBB. **Analysis of Other Options:** * **Option A (True):** At high doses, metoclopramide blocks **5HT3 receptors** in the Chemoreceptor Trigger Zone (CTZ), contributing to its antiemetic efficacy, especially in chemotherapy-induced nausea. * **Option B (True):** It acts as a **5HT4 agonist** on enteric neurons. This stimulates the release of Acetylcholine, increasing gastric motility and LES tone (prokinetic action). * **Option C (True):** Its **D2 blocking action** in the nigrostriatal pathway leads to **Extrapyramidal Side Effects (EPS)**, such as acute dystonia, especially in children and young adults. It also causes hyperprolactinemia (galactorrhea/gynecomastia). **High-Yield Facts for NEET-PG:** 1. **Mechanism Summary:** 5HT4 Agonism (Prokinetic), D2 Antagonism (Antiemetic/EPS), and 5HT3 Antagonism (High-dose Antiemetic). 2. **Site of Action:** It increases motility in the upper GI tract but has **no effect** on the large intestine. 3. **Drug of Choice:** Used for Diabetic Gastroparesis and as an adjunct in gastrointestinal radiological exams.

Question 196: Which drug combination is not rational for the management of acid peptic disease?

A. Ranitidine + Aluminum hydroxide
B. Ranitidine + Sucralfate (Correct Answer)
C. Ranitidine + Carbenoxolone
D. Ranitidine + Colloidal bismuth subcitrate

Explanation: ### Explanation The correct answer is **B. Ranitidine + Sucralfate**. #### 1. Why the combination is irrational **Sucralfate** is a complex of aluminum hydroxide and sulfated sucrose. It acts as a physical mucosal protectant by polymerizing into a sticky, viscous gel that binds to the ulcer base. This polymerization process is **acid-dependent**; it requires a gastric pH of **less than 4** to be activated. **Ranitidine** is an $H_2$ receptor antagonist that suppresses gastric acid secretion, thereby increasing the intragastric pH. When given together, Ranitidine raises the pH, preventing the activation of Sucralfate and rendering it ineffective. To avoid this interaction, Sucralfate should be taken at least 30 minutes before any acid-suppressing drug. #### 2. Analysis of Incorrect Options * **A. Ranitidine + Aluminum hydroxide:** Antacids like Aluminum hydroxide neutralize existing acid, while Ranitidine reduces further secretion. While they can be used in the same treatment plan, they are usually spaced apart to prevent the antacid from adsorbing the $H_2$ blocker. * **C. Ranitidine + Carbenoxolone:** Carbenoxolone (a licorice derivative) increases mucus production and mucosal life span. It does not require an acidic medium for its action, making the combination pharmacologically compatible. * **D. Ranitidine + Colloidal Bismuth Subcitrate (CBS):** CBS acts by coating the ulcer and has antimicrobial activity against *H. pylori*. Unlike Sucralfate, its efficacy is not significantly hampered by a rise in pH caused by $H_2$ blockers. #### 3. High-Yield Clinical Pearls for NEET-PG * **Sucralfate Side Effect:** The most common side effect is **constipation** (due to the aluminum content). * **Drug Interactions:** Sucralfate can adsorb other drugs (e.g., Digoxin, Tetracycline, Phenytoin, Fluoroquinolones). Always maintain a 2-hour gap. * **Proton Pump Inhibitors (PPIs):** Like $H_2$ blockers, PPIs also decrease the efficacy of Sucralfate due to pH elevation. * **Carbenoxolone Warning:** It has a steroid-like structure and can cause sodium and water retention (edema and hypertension).

Question 197: Which of the following agents is recommended for the medical treatment of variceal bleed?

A. Octreotide (Correct Answer)
B. Desmopressin
C. Vasopressin
D. Nitroglycerin

Explanation: **Explanation:** The primary goal in managing acute variceal bleeding is to reduce portal venous pressure. **Octreotide**, a synthetic long-acting analogue of somatostatin, is the preferred medical treatment. It works by inhibiting the release of vasodilator hormones (like glucagon), leading to **splanchnic vasoconstriction**. This reduces portal blood flow and pressure without the significant systemic side effects associated with other vasoconstrictors. **Analysis of Options:** * **Octreotide (Correct):** It is the drug of choice due to its efficacy and superior safety profile. It specifically targets the splanchnic circulation. * **Vasopressin:** While it is a potent splanchnic vasoconstrictor, it is rarely used now because it causes **non-selective systemic vasoconstriction**, leading to serious adverse effects like myocardial infarction, mesenteric ischemia, and limb ischemia. * **Desmopressin (DDAVP):** This is a selective V2 receptor agonist used for Diabetes Insipidus and von Willebrand disease. It lacks the V1-mediated vasoconstrictive properties required to treat variceal bleeds. * **Nitroglycerin:** This is a vasodilator. While sometimes used as an *adjunct* to vasopressin to reduce systemic side effects and further lower portal pressure, it is never used as a primary monotherapy for active bleeding. **High-Yield Clinical Pearls for NEET-PG:** * **Terlipressin:** A synthetic analogue of vasopressin with a longer half-life and fewer side effects. It is the only agent shown to **improve survival** in acute variceal bleeds. * **Prophylaxis:** While Octreotide/Terlipressin are for *acute* bleeds, **Propranolol or Nadolol** (non-selective beta-blockers) are used for the *primary and secondary prevention* of variceal hemorrhage. * **Antibiotics:** Prophylactic antibiotics (e.g., Ceftriaxone) are mandatory in cirrhotic patients with variceal bleeds to reduce mortality.

Question 198: Metoclopramide has the following actions EXCEPT:

A. Increase lower esophageal sphincter tone
B. Prokinetic action is blocked by atropine
C. Increase gastric peristalsis
D. Increase large intestinal peristalsis (Correct Answer)

Explanation: **Explanation:** Metoclopramide is a substituted benzamide that acts as a **prokinetic agent**. Its primary mechanism involves **D2 receptor antagonism** and **5-HT4 receptor agonism**, which enhances the release of acetylcholine (ACh) from the myenteric plexus. **Why Option D is Correct:** Metoclopramide’s prokinetic effect is localized to the **upper gastrointestinal tract**. It increases the motility of the esophagus, stomach, and small intestine but has **no significant effect on large intestinal motility** or colonic transit time. Therefore, it is ineffective in treating conditions like constipation or colonic pseudo-obstruction. **Analysis of Incorrect Options:** * **Option A:** It increases **Lower Esophageal Sphincter (LES) tone** by enhancing cholinergic transmission, making it useful in GERD. * **Option B:** Since its prokinetic action is mediated via the release of acetylcholine, its effects are **antagonized by atropine** (an anticholinergic). * **Option C:** It increases **gastric peristalsis** and promotes gastric emptying (gastrokinetic action) by coordinating antral contractions and relaxing the pyloric sphincter. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** It is both a prokinetic and a potent **antiemetic** (due to D2 blockade in the Chemoreceptor Trigger Zone). * **Side Effects:** Because it crosses the blood-brain barrier, it can cause **Extrapyramidal Side Effects (EPS)** like acute dystonia and parkinsonism, especially in children. * **Hyperprolactinemia:** D2 blockade in the pituitary can lead to increased prolactin, causing gynaecomastia or galactorrhea. * **Drug of Choice:** It is frequently used for **Diabetic Gastroparesis** and as a premedication for emergency surgery to prevent aspiration (Mendelson’s syndrome).

Question 199: Sucralfate does not interfere with the absorption of which of the following drugs?

A. Ciprofloxacin
B. Phenytoin
C. Phenoxymethylpenicillin (Correct Answer)
D. Digoxin

Explanation: **Explanation:** Sucralfate is a complex of **sulfated sucrose and aluminum hydroxide**. In an acidic environment (pH < 4), it undergoes polymerization to form a sticky, viscous gel that binds to the base of ulcer craters, providing a physical barrier against acid and pepsin. **Why Phenoxymethylpenicillin is the Correct Answer:** Sucralfate primarily interferes with the absorption of other drugs through two mechanisms: **chelation** (due to the aluminum content) and **physical adsorption** (trapping drugs within its viscous gel). **Phenoxymethylpenicillin (Penicillin V)** is an acid-stable penicillin that does not form significant complexes with aluminum nor is it significantly adsorbed by the sucralfate gel. Therefore, its bioavailability remains largely unaffected. **Why Other Options are Incorrect:** * **Ciprofloxacin:** Fluoroquinolones are notorious for chelating with polyvalent cations like $Al^{3+}$ found in sucralfate, leading to a massive reduction in absorption (up to 90%). * **Phenytoin:** Sucralfate can adsorb phenytoin onto its surface, significantly reducing its serum concentration and potentially leading to breakthrough seizures. * **Digoxin:** Similar to phenytoin, digoxin is physically adsorbed by the sucralfate polymer, decreasing its therapeutic efficacy. **High-Yield Clinical Pearls for NEET-PG:** * **The "2-Hour Rule":** To avoid drug-drug interactions, other oral medications should be administered at least **2 hours before** taking sucralfate. * **Activation Requirement:** Sucralfate requires an **acidic medium** to polymerize. Therefore, it should not be administered simultaneously with Antacids, H2 blockers, or PPIs. * **Side Effects:** The most common side effect is **constipation** (due to the aluminum moiety). It is not absorbed systemically, making it safe in pregnancy. * **Clinical Use:** Primarily used in duodenal ulcers and for preventing stress ulcers in ventilated patients (as it doesn't raise gastric pH, reducing the risk of nosocomial pneumonia).

Question 200: Constipation is caused by all of the following drugs except?

A. Neostigmine (Correct Answer)
B. Atropine
C. Morphine
D. Fentanyl

Explanation: **Explanation:** The correct answer is **Neostigmine**. To understand this, one must look at the effect of the Autonomic Nervous System (ANS) on the gastrointestinal tract. **1. Why Neostigmine is the correct answer:** Neostigmine is an **Anticholinesterase** (parasympathomimetic). It inhibits the enzyme acetylcholinesterase, leading to increased levels of Acetylcholine (ACh) at the muscarinic receptors in the gut [1]. ACh stimulates the M3 receptors on intestinal smooth muscles, increasing peristalsis and secretions. Therefore, Neostigmine **promotes bowel evacuation** (prokinetic effect) and is actually used clinically to treat paralytic ileus and Ogilvie’s syndrome. It causes diarrhea, not constipation. **2. Why the other options are incorrect:** * **Atropine:** This is a classic **Antimuscarinic** (parasympatholytic). By blocking M3 receptors, it decreases intestinal motility and secretions, leading to constipation [2]. * **Morphine & Fentanyl:** These are **Opioids**. Opioids cause significant constipation (Opioid-Induced Constipation) by acting on $\mu$-receptors in the myenteric plexus [3]. This results in decreased rhythmic contractions, increased segmental tone (which slows transit), and increased water absorption from the stool. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Constipation Mnemonics:** Remember **"ABC"** — **A**nticholinergics (Atropine), **B**arium sulfate, **C**alcium channel blockers (Verapamil is a notorious cause), and **O**pioids. * **Verapamil** is the CCB most commonly associated with constipation in exam questions. * **Methylnaltrexone** or **Alvimopan** are specific $\mu$-opioid antagonists used to treat opioid-induced constipation without reversing analgesia.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free